August 13, 2021 – TheNewswire - Ottawa, Ontario – Molecule Holdings Inc. MLCL MLCL EVRRF ("Molecule" or the "Company"), is pleased to announce that it has completed its previously announced non-brokered private placement of unsecured convertible debentures (each, a "Debenture", collectively the "Debentures") of the Company (the "Offering") for total gross proceeds of $2,434,000, exceeding its targeted minimum of $1,500,000. The Company had announced the closing of the first tranche (the "First Tranche") on August 4th, 2021 for gross proceeds of $1,414,000 and announces the closing of the second tranche (the "Second Tranche") for gross proceeds of $1,020,000.
The Debentures will mature on the date (the "Maturity Date") that is thirty-six (36) months from the date of issuance (the "Closing Date") and will bear interest at a simple rate of 8.00% per annum, payable semi-annually in cash within 30 days of each June 30th and December 31st until conversion or repayment. The holders of the Debentures are entitled to convert the Principal Amount of the Debentures at any time prior to the Maturity Date into common shares of the Company at a conversion price of $0.10 (the "Conversion Price"), subject to adjustment. As of the date that is four (4) months and one (1) day following the Closing Date, the Company will have a right to prepay or redeem the Principal Amount, in whole or in part, at par plus accrued and unpaid interest, without penalty.
For each $1,000 in principal amount (the "Principal Amount") of the Debentures, the holders received 6,000 share purchase warrants (each a "Warrant", collectively the "Warrants"), each Warrant entitling the holder thereof to acquire one common share of the Company (each a "Warrant Share", collectively the "Warrant Shares") at an exercise price of $0.15 per Warrant Share (the "Exercise Price") (subject to adjustment) for a period of thirty-six (36) months from the applicable Closing Date.
1,414 Debentures and 8,484,000 Warrants were issued in the First Tranche and 1,020 Debentures and 6,120,000 Warrants were issued in the Second Tranche for an aggregate 2,434 Debentures and 14,604,000 Warrants issued pursuant to the Offering. The Company also paid, in aggregate throughout the Offering, $126,320 in finder's commissions, $6,000 in advisory and referral fees and issued 1,263,200 non-transferable finder warrants (the "Finder Warrants") and 24,000 non-transferable advisory warrants (the "Advisory Warrants"). The Finder Warrants are exercisable at $0.10 per share for a period of thirty-six (36) months from the Closing Date and the Advisory Warrants are exercisable at $0.15 per share for a period of thirty-six (36) months from the Closing Date.
The Debentures, Warrants and the common shares issuable upon conversion of the Debentures or exercise of the Warrants, respectively, will be subject to a statutory hold period expiring on the date that is four months and one day after the Closing Date, expiring on December 1, 2021 with respect to the First Tranche and December 12, 2021 with respect to the Second Tranche.
The proceeds of the Offering are expected to be used for general working capital.
Subject to the policies of the Canadian Securities Exchange (the "CSE") and approval if required, the Debentures and the Warrants provide for anti-dilution adjustments, including corporate actions of the Company as well as future securities issuances below the Conversion Price or Exercise Price, as applicable, resulting in the decrease of the Conversion Price or Exercise Price respectively. Similarly, as a result of the issuance of the Debentures and Warrants pursuant to the Offering, the conversion and exercise prices of certain debentures and warrants, respectively, that were previously issued by the Company in March 2021 will be reduced pursuant to the anti-dilution terms thereof.
The Offering, in particular the First Tranche, constitutes a "related party transaction" as defined under Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101") as certain insiders of the Company subscribed for an aggregate of 125 Debentures (and corresponding Warrants) pursuant to the First Tranche of the Offering. The Company is relying on the exemptions from the valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(a) and 5.7(1)(a) of MI 61-101, as the fair market value of the participation in the Offering by insiders does not exceed 25% of the market capitalization of the Company, as determined in accordance with MI 61-101. The Company did not file a material change report in respect of the related party transaction at least 21 days before the closing of the Offering as the insider participation was only recently confirmed.
None of the securities issued in connection with the Offering will be registered under the United States Securities Act of 1933, as amended (the "1933 Act"), and none of them may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act. This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of the securities in any state where such offer, solicitation, or sale would be unlawful.
ON BEHALF OF THE BOARD
MOLECULE HOLDINGS INC.
Per: "Philip Waddington"
President, CEO and Director
For further information, please contact:
André Audet, Chairman and Co-Founder
Phone: 1 (888) 665-2853 x101
Email: andre@molecule.ca
About Molecule Holdings Inc.
Molecule works with client-partners to engage in the production of cannabis-infused beverages and edibles. We provide the infrastructure, know-how, technology, and licensing for craft producers to create consumable cannabis products. Molecule's goal is to be the on-ramp for companies wishing to enter into the cannabis beverage and edibles market, but who choose not to go through the significant process of obtaining the required cannabis licences.
Neither the Canadian Securities Exchange nor its regulation services provider accepts responsibility for the adequacy or accuracy of this press release.
Forward-Looking Statements
Certain statements contained in this news release may constitute forward-looking information.
Forward-looking information is often, but not always, identified by the use of words such as "anticipate", "plan", "estimate", "expect", "may", "will", "intend", "should", and similar expressions. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information. The Company's actual results could differ materially from those anticipated in this forward-looking information as a result of regulatory decisions, competitive factors in the industries in which the Company operates, prevailing economic conditions, and other factors, many of which are beyond the control of the Company. In this news release, the Company is making forward-looking statements with respect to the Offering, including but not limited to the terms thereof and use of proceeds. The Company believes that the expectations reflected in the forward-looking information are reasonable, but no assurance can be given that these expectations will prove to be correct and such forward-looking information should not be unduly relied upon. Any forward-looking information contained in this news release represents the Company's expectations as of the date hereof and is subject to change after such date. The Company disclaims any intention or obligation to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required by applicable securities legislation.
Copyright (c) 2021 TheNewswire - All rights reserved.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
